度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 12 月 10 日，深圳开立生物医疗科技股份有限公司（以下简称"公 司"）第四届董事会第十三次会议和第四届监事会第十二次会议，分别审议通过 了《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》，现将有关 情况公告如下： 证券代码：300633 证券简称：开立医疗 公告编号：2025-056 深圳开立生物医疗科技股份有限公司 关于修订《公司章程》并办理工商变更登记及修订和制定部分治理制 本次修订《公司章程》尚需提交公司股东大会审议，公司董事会提请股东大 会授权公司管理层具体办理《公司章程》及其工商变更登记、章程备案等相关事 宜。授权的有效期限自公司股东大会审议通过之日起至本次相关工商变更登记及 章程备案办理完毕之日止。 三、制定和修订公司部分治理制度的情况 为进一步完善公司治理结构，更好地促进公司规范运作，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司独立董事管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-054 深圳开立生物医疗科技股份有限公司 关于召开 2025 年第二次临时股东大会的通知 1、股东大会届次：2025 年第二次临时股东大会 2、股东大会的召集人：公司董事会；公司第四届董事会第十三次会议审议 通过了《关于提请召开 2025 年第二次临时股东大会的议案》。 3、会议召开的合法、合规性：公司董事会认为，本次会议的召集、召开符 合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政 法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议：2025 年 12 月 30 日（星期二）下午 14:30 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 12 月 30 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易 所互联网系统投票的具体时间为 2025 年 12 月 30 日 9:15-15:00 期间的任意时间。 5、会议的召开方 ...

深圳开立生物医疗科技股份有限公司 证券代码：300633 证券简称：开立医疗 公告编号：2025-053 第四届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025 年 12 月 10 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第四届监事会第十二次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼 会议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 三、备查文件 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）发布的《关于 修订<公司章程>并办理工商变更登记及修订和制定部分治理制度的公告》。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 2、审议通过《关于部分募集资金投资项目延期的议案》 经审议，监事会认为：公司本次募投项目延期事项是本着对公司及股东利益 负责的原则，结合募投项目建设的实际情况提出的，不存在改变或变相 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-052 深圳开立生物医疗科技股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 12 月 10 日，深圳开立生物医疗科技股份有限公司（以下简称"公 司"）第四届董事会第十三次会议以现场和通讯表决相结合的方式在深圳市光明 区光电北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2025 年 12 月 5 日以电话、电子邮件等方式通知全体董事。 本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 二、董事会会议审议情况 （8）修订《关联交易管理办法》 表决结果：7 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 经与会董事投票表决，审议通过了如下决议： 1、审议通过《关于取消监事会、修订<公司章程>并办理工商变更登记的议 案》 根据《中华人民共和国公司法》《上市公司章程指引》《上 ...

长城证券股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意深圳开立生物医疗科技股份有 限公司向特定对象发行股票注册的批复》（证监许可[2021]668 号）核准，公司 向特定对象发行人民币普通股（A 股）27,851,745 股，发行价格为 27.79 元/股， 募集资金总额为人民币 773,999,993.55 元，扣除发行费用（不含税）合计人民币 4,944,026.20 元后，募集资金净额为人民币 769,055,967.35 元，其中计入股本 27,851,745.00 元，计入资本公积（股本溢价）741,204,222.35 元。天健会计师事 务所（特殊普通合伙）对以上募集资金到账情况出具了《深圳开立生物医疗科技 股份有限公司验资报告》（天健验[2021]3-78 号）。 | 序号 | 募投项目 | 拟使用募集资 | 截至 2024.09.30 | 截至 2024.09.30 | | --- | --- | --- | --- | --- | | | | 金投入金额 | 累计投入金额 | 投入比例 | | 1 | 彩超、内窥镜产品研发项目 | 24,211.03 | 24, ...

Investment Rating - The report maintains an "Overweight" rating for the industry [1][5]. Core Insights - The medical device procurement scale continues to grow, driven by ongoing equipment update policies, which are expected to lead to a long-term increase in procurement levels. The report recommends medical device companies that are likely to benefit from these policies, including Mindray Medical, United Imaging, Kaili Medical, and Aohua Endoscopy [3][5]. - In November 2025, the new equipment procurement scale showed significant year-on-year growth: MRI increased by 11.1%, CT by 26.4%, DR by 47.2%, ultrasound by 17.0%, while endoscopes declined by 4.9%, and surgical robots grew by 8.6%. Cumulatively, from January to November 2025, MRI grew by 50.4%, CT by 72.7%, DR by 74.0%, ultrasound by 56.1%, endoscopes by 19.7%, and surgical robots by 32.8% [5]. - The equipment update policy is expected to drive procurement levels significantly, with a target of over 25% growth in medical equipment investment by 2027 compared to 2023. This policy is expected to enhance the configuration of high-end equipment to levels comparable to middle-income countries [5]. - The domestic market is showing signs of recovery, with a notable increase in procurement demand from medical institutions, reflecting a positive trend in the medical equipment industry. For instance, United Imaging reported a revenue of 6.866 billion yuan in the domestic market for the first three quarters of 2025, representing a year-on-year growth of 23.7% [5]. Summary by Sections - **Investment Recommendations**: The report suggests maintaining an "Overweight" rating and recommends companies likely to benefit from the equipment update policies [5]. - **Market Trends**: The report highlights the growth in procurement scale for various medical devices, indicating a robust market environment [5]. - **Policy Impact**: The ongoing implementation of equipment update policies is expected to significantly enhance procurement levels in the medical sector [5].

Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with a slight increase in revenue but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of December 10, 2025, Kaili Medical's stock closed at 26.81 yuan, with a slight increase of 0.3% [1]. - The trading volume was 18,500 hands, with a total transaction amount of 49.37 million yuan [1]. - On December 10, the net inflow of main funds was 4.96 million yuan, accounting for 10.05% of the total transaction amount [1]. - Retail investors experienced a net outflow of 4.06 million yuan, representing 8.23% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 15 institutions provided ratings for Kaili Medical, with 10 buy ratings and 5 hold ratings [2]. - The average target price set by institutions over the past 90 days is 4.128 billion yuan [2].

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [36]. Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, along with the first version of the Commercial Health Insurance Innovative Drug List, was released on December 7, 2025. This adjustment includes 114 new drugs, of which 50 are classified as Class 1 innovative drugs [3]. - The newly launched Chinese Drug Price Registration System aims to facilitate the global pricing system for innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients [4][5]. - The innovative drug sector is expected to continue its rise, with recommendations to focus on companies with rich pipeline layouts, high-potential innovative drugs, and leading technology platforms [11]. Summary by Sections Industry Developments - The 2025 drug list adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and innovation in China [3]. - The Chinese Drug Price Registration System, launched on December 2, 2025, allows pharmaceutical companies to independently declare drug prices, promoting a more transparent and globalized pricing structure [4][5]. Company Highlights - Yino Pharmaceutical has rapidly emerged in the metabolic disease treatment field since its establishment in 2014, with its core product, Isupreglutide α, receiving approval as a Class 1 innovative drug and entering commercialization [7]. Investment Strategy - The report suggests focusing on companies with diverse pipelines, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group, as well as those with high-potential innovative drugs like Sanofi and Kaiyin Technology [11]. - It also highlights the importance of companies with leading technology platforms, such as Dongcheng Pharmaceutical and WuXi AppTec, as well as upstream companies benefiting from overseas expansion [11]. Market Performance - The pharmaceutical sector experienced a decline of 0.74% last week, ranking 19th among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.28% [14][24]. - As of December 5, 2025, the pharmaceutical sector's valuation stands at 29.30 times (TTM), with a premium of 17.46% over the overall A-share market [27].

Core Viewpoint - The stock of Kaili Medical (300633) has shown a slight increase of 1.04% on December 8, 2025, with a closing price of 27.22 yuan, indicating a mixed sentiment in the market regarding the company's performance and future prospects [1]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, a year-on-year increase of 4.37% [3]. - The net profit attributable to shareholders was 33.51 million yuan, reflecting a significant year-on-year decline of 69.25% [3]. - The company's third-quarter revenue was 495 million yuan, up 28.42% year-on-year, but the net profit for the quarter was negative at -13.52 million yuan, although this represented a year-on-year improvement of 78.05% [3]. - The company's gross profit margin stands at 60.36%, which is higher than the industry average of 51.22% [3]. Market Activity - On December 8, 2025, the net inflow of main funds was 6.65 million yuan, accounting for 9.27% of the total transaction amount, while retail investors experienced a net outflow of 0.08 million yuan [1][2]. - Over the past five days, the stock has seen fluctuations in fund flows, with varying levels of net inflow and outflow from different investor categories [2]. Industry Comparison - Kaili Medical's total market capitalization is 11.778 billion yuan, slightly above the industry average of 11.014 billion yuan, ranking 27th out of 124 companies in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) is 263.61, significantly higher than the industry average of 65.06, indicating potential overvaluation [3]. - The return on equity (ROE) for Kaili Medical is 1.07%, which is considerably higher than the industry average of 0.15%, suggesting better efficiency in generating profits from equity [3]. Analyst Ratings - In the last 90 days, 15 institutions have rated the stock, with 10 giving a "buy" rating and 5 an "accumulate" rating, indicating a generally positive outlook among analysts [4]. - The average target price set by analysts over the past 90 days is 41.28 yuan, suggesting potential upside from the current trading price [4].